Skeletal aspects of Gaucher disease: a review

被引:175
作者
Wenstrup, RJ
Roca-Espiau, M
Weinreb, NJ
Bembi, B
机构
[1] Childrens Hosp Res Fdn, Div & Program Human Genet, Cincinnati, OH 45229 USA
[2] Hosp Miguel Servet, Dept Radiol, Musculoskeletal MRI Sect, Zaragoza, Spain
[3] Univ Gaucher Res Fdn Inc, Univ Gaucher Treatment Ctr, Tamarac, FL USA
[4] Burlo Garofolo Inst, Trieste, Italy
关键词
D O I
10.1259/bjr.75.suppl_1.750002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In Gaucher disease. a genetic deficiency in the activity of the lysosomal enzyme beta-glucocerebrosidase (acid beta-glucosidase) causes monocytes and macrophages to store excessive amounts of glucocerebroside in lysosomes. The resulting distended cells are called Gaucher cells. and the pathology associated with this condition stems from the accumulation of Gaucher cells in organ systems. The skeletal manifestations are probably the most disabling aspect of the disease. Patients commonly experience bone pain, some suffer bone crises. and up to 20%, have impaired mobility. Radiological findings include Erlenmeyer flask deformity, Osteopenia. osteosclerosis. osteonecrosis. fractures and bone marrow infiltration. Findings from the Gaucher Registry show that nearly all patients with Gaucher disease have radiological evidence of skeletal involvement, and the majority have a history of serious skeletal complications, Skeletal involvement follows three basic processes: focal disease (irreversible lesions such as osteonecrosis and osteosclerosis), local disease (reversible abnormalities adjacent to heavily involved marrow such is cortical thinning and long bone deformity) and generalized osteopenia. Infarctions are involved in sonic of the skeletal manifestations, but the mechanisms causing high rates of bone turnover and failure of remodelling are not known. The availability of a beta-glueocerebrosidase-deficient mouse model of Gaucher disease with long-term survival should help elucidate the skeletal Pathology in Gaucher disease and may ultimately lead to improved management of skeletal complications.
引用
收藏
页码:A2 / A12
页数:11
相关论文
共 45 条
[11]   The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease [J].
Charrow, J ;
Andersson, HC ;
Kaplan, P ;
Kolodny, EH ;
Mistry, P ;
Pastores, G ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ ;
Zimran, A .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (18) :2835-2843
[12]   Novel strategies for the treatment of osteoarthritis [J].
Chikanza, IC ;
Fernandes, L .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (07) :1499-1510
[13]   Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement [J].
Ciana, G ;
Cuttini, M ;
Bembi, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (10) :712-712
[14]   Gaucher's disease: clinical features and natural history [J].
Cox, TM ;
Schofield, JP .
BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (04) :657-689
[15]  
Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002
[16]   IDIOPATHIC BONE NECROSIS OF THE FEMORAL-HEAD - EARLY DIAGNOSIS AND TREATMENT [J].
FICAT, RP .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1985, 67 (01) :3-9
[17]   Bone markers [J].
Garnero, P ;
Delmas, PD .
BAILLIERES CLINICAL RHEUMATOLOGY, 1997, 11 (03) :517-537
[18]   SELECTIVE EFFECTS OF GLUCOCEREBROSIDE (GAUCHERS STORAGE MATERIAL) ON MACROPHAGE CULTURES [J].
GERY, I ;
ZIGLER, JS ;
BRADY, RO ;
BARRANGER, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1182-1189
[19]   Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement [J].
Hermann, G ;
Pastores, GM ;
Abdelwahab, IF ;
Lorberboym, AM .
SKELETAL RADIOLOGY, 1997, 26 (12) :687-696
[20]   Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease [J].
Hollak, CEM ;
Evers, L ;
Aerts, JMFG ;
vanOers, MHJ .
BLOOD CELLS MOLECULES AND DISEASES, 1997, 23 (11) :201-212